|
(viii)
|
Stephen A. Schwarzman
|
c/o The Blackstone Group Inc.
345 Park Avenue
New York, NY
10154
Citizenship: United States
Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of
Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP
L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstones senior managing directors
and controlled by its founder, Stephen A. Schwarzman.
Each such Reporting Person may be deemed to beneficially own the shares of Common
Stock (as defined below) beneficially owned by Clarus Lifesciences III, L.P. directly or indirectly controlled by it or him, but neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any
Reporting Person (other than Clarus Lifesciences III, L.P. to the extent it directly holds Common Stock) is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as
amended (the Act), or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares. The filing of this statement should not be construed to be an admission that any member of the
Reporting Persons are members of a group for the purposes of Sections 13(d) and 13(g) of the Act.
Item 2(d).
|
Title of Class of Securities:
|
Common Stock, par value $0.0001 per share (the Common Stock).
38942Q103
Item 3.
|
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
(a) Amount beneficially owned:
Calculations of the percentage of shares of Common Stock beneficially owned assume 20,979,265 shares of Common Stock
outstanding as of November 6, 2020, as reported in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020. Each of the Reporting Persons may be
deemed to be the beneficial owner of the shares of Common Stock listed on such Reporting Persons cover page.
Clarus Lifesciences
III, L.P. directly holds 1,930,395 shares of Common Stock.
(b) Percent of class:
Each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Common Stock listed on such
Reporting Persons cover page.
(c) Number of Shares as to which the Reporting Person has:
(i) Sole power to vote or to direct the vote:
See each cover page hereof.